Standard BioTools Inc.

Standard BioTools Inc.

0.62
USD
-0.09
(-12.21%)
-0.10EPS
2.17P/E
292.29MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of September 30, 2026, Standard BioTools Inc. carries a market capitalization of 292.29M, placing it among publicly traded companies globally. Its enterprise value stands at -141.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap292.29M
Enterprise Value-141.98M

Important Dates

Standard BioTools Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of September 30, 2026, Standard BioTools Inc. has 394.67M shares outstanding.

Shares Outstanding394.67M

Valuation Ratios

As of September 30, 2026, Standard BioTools Inc. trades at a trailing price-to-earnings ratio of 2.17. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 0.53.

PE Ratio2.17
PS Ratio3.42
PB Ratio0.53
P/TBV Ratio0.53
P/FCF Ratio-4.39
P/OCF Ratio-4.49

Financial Position

As of September 30, 2026, Standard BioTools Inc. maintains a current ratio of 9.75, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.83, indicating elevated leverage, while an interest coverage ratio of -15,424.20 demonstrates limited ability to service its debt obligations.

Current Ratio9.75
Quick Ratio9.29
Debt / Equity4.83
Debt / EBITDA-0.35
Interest Coverage-15,424.20

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Standard BioTools Inc. posted a return on equity (ROE) of 27.86, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 22.65, measuring how efficiently the asset base is converted into earnings. The company generates approximately 217,043.70 in revenue per employee across its workforce of 389.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.88 indicates how many times Standard BioTools Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)27.86
Return on Assets (ROA)22.65
Revenue Per Employee217,043.70
Employee Count389.00
Inventory Turnover1.88

Taxes

USD

Over the twelve months ended September 30, 2026, Standard BioTools Inc. recorded an income tax benefit of -35.80M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -73.03M and 133.08M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-35.80M

Stock Price Statistics

USD

As of the close on November 16, 2026, Standard BioTools Inc.'s stock has declined approximately 49.92% over the past 52 weeks. The 50-day moving average sits at 0.68, while the 200-day moving average is 0.87.

52-Week Price Change-49.92%
50-Day Moving Average0.68
200-Day Moving Average0.87

Income Statement

USD

Over the twelve months ended September 30, 2026, Standard BioTools Inc. generated 84.43M in revenue and converted that into 133.08M in net income, yielding earnings per share of -0.10. EBITDA reached -77.12M, while operating income came in at -47.26M.

Revenue84.43M
Gross Profit44.05M
Operating Income-47.26M
Pretax Income-73.03M
Net Income133.08M
EBITDA-77.12M
EBIT-82.30M
Earnings Per Share (EPS)-0.10

Balance Sheet

USD

As of September 30, 2026, Standard BioTools Inc. holds 461.11M in cash and equivalents against 26.83M in total debt, resulting in a net debt position of -267.19M. Total book value stands at 555.75M, with working capital of 446.28M providing operational flexibility.

Cash & Cash Equivalents461.11M
Total Debt26.83M
Net Debt-267.19M
Equity (Book Value)555.75M
Book Value Per Share1.41
Working Capital446.28M

Cash Flow

USD

Standard BioTools Inc. produced -64.26M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.39M in capital expenditures, free cash flow totaled -65.65M - equivalent to -0.17 per share.

Operating Cash Flow-64.26M
Capital Expenditures-1.39M
Free Cash Flow-65.65M
FCF Per Share-0.17

Margins

Over the twelve months ended September 30, 2026, Standard BioTools Inc. posted a gross margin of 52.18, reflecting its pricing power and cost economics. The operating margin of -55.98 and net profit margin of 157.62 provide insight into operational efficiency.

Gross Margin52.18
Operating Margin-55.98
Pretax Margin-86.50
Profit Margin157.62
EBITDA Margin-91.34

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -22.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Standard BioTools Inc. shareholders.

Shareholder Yield0.05
FCF Yield-22.76

Scores

As of September 30, 2026, Standard BioTools Inc. has an Altman Z-Score of 0.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.41